For Resilience, the deal adds 300 skilled employees, as well as over 200,000 sq ft of manufacturing, office, process development, and quality assurance/control space across locations in Florida, California, and Maryland. Additional expansion projects are also underway, according to the company.

Alachua, FL-based Ology Bio develops and manufactures drugs and biologics for commercial customers, as well as the U.S. government. It has been awarded more than $1.8 billion in government contracts, including a $37 million contract in November to develop an anti-COVID-19 monoclonal antibody cocktail, according to Resilience.

Resilience customers can utilize Ology Bio's services, including regulatory support from preclinical development through licensure, clinical trial operations support, bioanalytical testing, as well as current good manufacturing practice manufacturing up to Biosafety Level 3, the company said. Ology Bio can manufacture cell and gene therapies, live viral vaccines and vectors, oncolytic viruses, plasmids, and monoclonal antibodies.